Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.

Merkel DG, Nagler A.

Expert Rev Anticancer Ther. 2014 Jul;14(7):817-29. doi: 10.1586/14737140.2014.896208. Epub 2014 Mar 18. Review.

PMID:
24641787
2.

Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Leitch HA.

Drugs. 2011 Jan 22;71(2):155-77. doi: 10.2165/11585280-000000000-00000. Review.

PMID:
21275444
3.

Efficacy and safety of deferasirox in myelodysplastic syndromes.

Breccia M, Alimena G.

Ann Hematol. 2013 Jul;92(7):863-70. doi: 10.1007/s00277-013-1703-7. Epub 2013 Feb 17. Review.

PMID:
23417759
4.

Iron chelation therapy in MDS: what have we learnt recently?

Schmid M.

Blood Rev. 2009 Dec;23 Suppl 1:S21-5. doi: 10.1016/S0268-960X(09)70006-2. Review.

PMID:
20116636
5.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
6.
7.

Iron chelation therapy for patients with myelodysplastic syndrome.

Yeh SP, Yang YS, Yao CY, Peng CT.

Hemoglobin. 2009;33(5):339-45. doi: 10.3109/03630260903212654. Review.

PMID:
19814680
8.

Myelodysplastic syndromes: iron overload consequences and current chelating therapies.

Greenberg PL.

J Natl Compr Canc Netw. 2006 Jan;4(1):91-6. Review.

PMID:
16403408
9.

Iron chelation therapy in myelodysplastic syndromes.

Fausel CA.

Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 2):S10-4; quiz S16. doi: 10.2146/ajhp090654.

PMID:
20332500
10.

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P; GFM (Groupe Francophone des Myélodysplasies).

Leuk Res. 2010 Jul;34(7):864-70. doi: 10.1016/j.leukres.2009.12.004. Epub 2010 Feb 2.

PMID:
20129667
11.

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.

Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.

Free Radic Biol Med. 2012 Aug 15;53(4):643-8. doi: 10.1016/j.freeradbiomed.2012.06.006. Epub 2012 Jun 15.

PMID:
22705364
12.

Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations.

Nolte F, Angelucci E, Breccia M, Gattermann N, Santini V, Vey N, Hofmann WK.

Leuk Res. 2015 Oct;39(10):1028-33. doi: 10.1016/j.leukres.2015.06.008. Epub 2015 Jun 20. Review.

PMID:
26293555
13.

Management of transfusion-related iron overload in patients with myelodysplastic syndromes.

Shah J, Kurtin SE, Arnold L, Lindroos-Kolqvist P, Tinsley S.

Clin J Oncol Nurs. 2012 Jun;16 Suppl:37-46. doi: 10.1188/12.CJON.S1.37-46. Review.

14.

Iron overload and chelation therapy in myelodysplastic syndromes.

Temraz S, Santini V, Musallam K, Taher A.

Crit Rev Oncol Hematol. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24. Review.

PMID:
24529413
15.

Controversies surrounding iron chelation therapy for MDS.

Leitch HA.

Blood Rev. 2011 Jan;25(1):17-31. doi: 10.1016/j.blre.2010.09.003. Epub 2010 Oct 27. Review.

PMID:
21030120
16.

[The role of iron metabolism in myelodysplastic syndromes].

Finelli C, Clissa C, Stanzani M.

Recenti Prog Med. 2014 Mar;105(3):123-6. doi: 10.1701/1434.15874. Italian.

PMID:
24675455
17.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
18.

Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Mitchell M, Gore SD, Zeidan AM.

Expert Rev Hematol. 2013 Aug;6(4):397-410. doi: 10.1586/17474086.2013.814456. Review.

19.

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.

Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R.

Leuk Res. 2013 Dec;37(12):1612-5. doi: 10.1016/j.leukres.2013.07.021. Epub 2013 Aug 9.

PMID:
23937987
20.

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Leitch HA, Vickars LM.

Hematology Am Soc Hematol Educ Program. 2009:664-72. doi: 10.1182/asheducation-2009.1.664. Review.

PMID:
20008252
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk